NASDAQ:DARE Daré Bioscience - DARE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Daré Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.27 +0.03 (+2.41%) (As of 01/31/2023 10:57 AM ET) Add Compare Share Share Today's Range$1.26▼$1.2850-Day Range$0.82▼$1.3652-Week Range$0.82▼$1.88Volume87,351 shsAverage Volume485,148 shsMarket Capitalization$108.15 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Daré Bioscience MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside629.2% Upside$9.33 Price TargetShort InterestHealthy1.39% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.13Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.32) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 starsMedical Sector618th out of 1,055 stocksPharmaceutical Preparations Industry311th out of 518 stocks 3.5 Analyst's Opinion Consensus RatingDaré Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.33, Daré Bioscience has a forecasted upside of 629.2% from its current price of $1.28.Amount of Analyst CoverageDaré Bioscience has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.39% of the outstanding shares of Daré Bioscience have been sold short.Short Interest Ratio / Days to CoverDaré Bioscience has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Daré Bioscience has recently decreased by 13.24%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDaré Bioscience does not currently pay a dividend.Dividend GrowthDaré Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DARE. Previous Next 4.0 News and Social Media Coverage News SentimentDaré Bioscience has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Daré Bioscience this week, compared to 1 article on an average week.Search Interest13 people have searched for DARE on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.MarketBeat Follows10 people have added Daré Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Daré Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Daré Bioscience is held by insiders.Percentage Held by InstitutionsOnly 9.19% of the stock of Daré Bioscience is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Daré Bioscience are expected to decrease in the coming year, from ($0.32) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Daré Bioscience is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Daré Bioscience is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDaré Bioscience has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Daré Bioscience (NASDAQ:DARE) StockDaré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.Read More Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address DARE Stock News HeadlinesJanuary 27, 2023 | msn.comDare County woman wins $150K on scratch ticketJanuary 26, 2023 | finance.yahoo.comDaré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of MenopauseJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 25, 2023 | msn.comDaré Bioscience hits seven-month high after regaining listing complianceJanuary 21, 2023 | finance.yahoo.comDaré Bioscience (NASDAQ:DARE) investors are sitting on a loss of 49% if they invested five years agoJanuary 10, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Daré Bioscience (DARE)January 10, 2023 | msn.comDaré Bioscience Shares Move Higher Intravaginal Ring Shows Promise In Menopause SymptomsJanuary 9, 2023 | finance.yahoo.comAll You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong BuyJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 9, 2023 | finance.yahoo.comDaré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of MenopauseJanuary 7, 2023 | forbes.comDare BioscienceDecember 13, 2022 | msn.comHC Wainwright & Co. Maintains Buy Rating for Dare Bioscience: Here's What You Need To KnowNovember 15, 2022 | finance.yahoo.comDare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?November 15, 2022 | finance.yahoo.comDaré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal HealthNovember 14, 2022 | finance.yahoo.comDaré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical StudyNovember 11, 2022 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Daré Bioscience (DARE)November 11, 2022 | seekingalpha.comDare Bioscience, Inc. (DARE) Q3 2022 Earnings Call TranscriptNovember 10, 2022 | finance.yahoo.comDaré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company UpdateNovember 10, 2022 | finance.yahoo.comDare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue EstimatesNovember 8, 2022 | finance.yahoo.comDaré Bioscience to Present at the Stifel 2022 Healthcare ConferenceNovember 3, 2022 | msn.comDare 2 Care helps fund Leeza’s Care ConnectionNovember 3, 2022 | msn.com‘Truth or Dare’ Director Alek Keshishian Says Madonna Asked for a Sequel, but ‘We Just Didn’t See Eye to Eye’November 3, 2022 | finance.yahoo.comDaré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022November 1, 2022 | finance.yahoo.comDaré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder CompleteOctober 25, 2022 | benzinga.comCan This Company's Birth Control Patch Disrupt The Contraceptive Market?October 19, 2022 | msn.comFair Oaks man accused of murder in fentanyl death of Auburn womanOctober 17, 2022 | finance.yahoo.comDaré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 StudySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address DARE Company Calendar Last Earnings11/10/2022Today1/31/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DARE CUSIPN/A CIK1401914 Webwww.darebioscience.com Phone(858) 926-7655Fax617-494-1544Employees16Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.33 High Stock Price Forecast$17.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+331.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,700,000.00 Net MarginsN/A Pretax Margin-245.47% Return on Equity-76.11% Return on Assets-47.49% Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book2.50Miscellaneous Outstanding Shares84,820,000Free Float81,432,000Market Cap$108.15 million OptionableNot Optionable Beta1.17 Key ExecutivesSabrina Martucci JohnsonPresident, CEO, Secretary & DirectorMark WaltersVice President-OperationsLisa Walters-HoffertChief Financial OfficerChristine MauckMedical DirectorDavid FriendChief Scientific OfficerKey CompetitorsImmunoPrecise AntibodiesNASDAQ:IPAParatek PharmaceuticalsNASDAQ:PRTKWerewolf TherapeuticsNASDAQ:HOWLNuvectis PharmaNASDAQ:NVCTSpectrum PharmaceuticalsNASDAQ:SPPIView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 30,299 shares on 11/15/2022Ownership: 4.166%Price T Rowe Associates Inc. MDBought 67,300 shares on 11/15/2022Ownership: 0.148%Renaissance Technologies LLCBought 283,400 shares on 11/14/2022Ownership: 0.766%UBS Group AGBought 55,992 shares on 11/10/2022Ownership: 0.067%Virtu Financial LLCBought 15,423 shares on 11/7/2022Ownership: 0.080%View All Institutional Transactions DARE Stock - Frequently Asked Questions Should I buy or sell Daré Bioscience stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DARE shares. View DARE analyst ratings or view top-rated stocks. What is Daré Bioscience's stock price forecast for 2023? 4 analysts have issued 12 month price objectives for Daré Bioscience's stock. Their DARE share price forecasts range from $4.00 to $17.00. On average, they anticipate the company's share price to reach $9.33 in the next year. This suggests a possible upside of 649.7% from the stock's current price. View analysts price targets for DARE or view top-rated stocks among Wall Street analysts. How have DARE shares performed in 2023? Daré Bioscience's stock was trading at $0.83 at the beginning of 2023. Since then, DARE shares have increased by 50.0% and is now trading at $1.2450. View the best growth stocks for 2023 here. Are investors shorting Daré Bioscience? Daré Bioscience saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 1,180,000 shares, a decline of 13.2% from the December 31st total of 1,360,000 shares. Based on an average trading volume of 229,500 shares, the days-to-cover ratio is currently 5.1 days. View Daré Bioscience's Short Interest. When is Daré Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our DARE earnings forecast. How were Daré Bioscience's earnings last quarter? Daré Bioscience, Inc. (NASDAQ:DARE) posted its earnings results on Thursday, November, 10th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. What other stocks do shareholders of Daré Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE). What is Daré Bioscience's stock symbol? Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE." Who are Daré Bioscience's major shareholders? Daré Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Daré Bioscience? Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Daré Bioscience's stock price today? One share of DARE stock can currently be purchased for approximately $1.25. How much money does Daré Bioscience make? Daré Bioscience (NASDAQ:DARE) has a market capitalization of $105.61 million and generates $10 million in revenue each year. The biotechnology company earns $-38,700,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. How can I contact Daré Bioscience? Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The official website for the company is www.darebioscience.com. The biotechnology company can be reached via phone at (858) 926-7655, via email at innovations@darebioscience.com, or via fax at 617-494-1544. This page (NASDAQ:DARE) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.